These findings illuminate the intracellular mechanisms involved in BMP2-mediated chemosensitization to TMZ in GBM, offering potential avenues for targeted therapeutic strategies against TMZ resistance in GBM. The gene discussed is BMP2; the disease is glioblastoma.